Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome

Published:2024-11 Issue: Volume:413 Page:125743
ISSN:0167-7322
Container-title:Journal of Molecular Liquids
language:en
Short-container-title:Journal of Molecular Liquids

Author:

Semenov Konstantin N.^ORCID,Prokopiev Ilya A.^ORCID,Petukhova Natalya V.^ORCID,Kremenetskaya Uliana A.,Senichkina Dina A.^ORCID,Epifanovskaya Olga S.,Rumiantsev Andrei M.,Andoskin Pavel A.,Rizaev Jasur A.,Kholmurodova Dilafruz K.,Ageev Sergei V.,Anufrikov Yurii A.,Zakharov Egor E.,Moiseev Ivan S.,Sharoyko Vladimir V.

Funder

Ministry of Health of the Russian Federation

Publisher

Elsevier BV

Reference71 articles.

1. Biochemistry and secondary metabolites;Elix,2008

2. Hawksworth, D. L. Supplement to “Chemical and Botanical Guide to Lichen Products”. By Chicita F. Culberson. The American Bryological and Lichenological Society (Reprinted from Bryologist, 73: (177–377). 1970. The Lichenologist 5, 179–179 (1971).

3. Secondary metabolism in the lichen symbiosis;Calcott;Chem. Soc. Rev.,2018

4. Yasuhiko Asahina (1880–1975) and His Studies on lichenology and chemistry of lichen metabolites on JSTOR;Shibata;Bryologist,2000

5. Atranorin - an interesting lichen secondary metabolite;Studzinska-Sroka;Mini-Rev. Med. Chem.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP